RxDoctor Payments Data

Jeffrey Rowand, MD

Family Medicine · Dallastown, PANPI 1245523034

Payments from drug & device makers

$9,633in general payments, 2019–2025

Across 595 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • GSK$991
  • Pfizer$930
  • AstraZeneca$859
  • Lilly USA, LLC$683
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$9,621100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,633 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$328,567
Medicare patients
375
Services billed
13,003

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban335$342,851
JardianceEmpagliflozin90$118,809
Trelegy ElliptaFluticasone/Umeclidin/Vilanter115$108,222
OzempicSemaglutide46$66,876
MounjaroTirzepatide45$63,992
OtezlaApremilast11$54,437
GlyxambiEmpagliflozin/Linagliptin42$47,500
Trijardy XrEmpaglifloz/Linaglip/Metformin35$42,516
TrulicityDulaglutide27$39,766
XareltoRivaroxaban35$38,623
Soliqua 100-33Insulin Glargine/Lixisenatide40$37,203
Tresiba Flextouch U-200Insulin Degludec21$26,242
Synjardy XrEmpagliflozin/Metformin Hcl18$25,892
Breo ElliptaFluticasone/Vilanterol52$24,638
FarxigaDapagliflozin Propanediol15$23,044

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$930$342,851335 claims
Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr, Synjardy Xr$296$234,718185 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Anoro Ellipta, Shingrix$991$162,946261 claims
Lilly USA, LLCMounjaro, Trulicity$683$103,75772 claims
Novo NordiskOzempic$1,033$66,87646 claims
AmgenOtezla$306$54,43711 claims
AstraZenecaFarxiga, Breztri Aerosphere$859$45,29542 claims
Johnson & JohnsonXarelto$441$38,62335 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$161$37,20340 claims
Astellas Pharma US IncMyrbetriq$263$12,31114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Dallastown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →